BioDelivery Sciences International Release: BEMA(TM) LA Achieves Therapeutic Plasma Concentrations In Phase I Trial: Complementary Pain Therapy To Phase III BEMA(TM) Fentanyl Product

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) reports positive proof of concept pharmacokinetic study conducted in normal volunteers with the company’s BEMA(TM) Long Acting Analgesic product (known as BEMA(TM) LA). The active ingredient contained within BEMA(TM) LA met the company’s expectations in terms of the amount absorbed into the bloodstream. Plasma concentrations (amount of active ingredient in the blood) were well within the levels associated with analgesic activity. Accordingly, BDSI now intends to actively explore the scale-up of manufacturing of the product for clinical efficacy and safety studies in patients with acute and chronic pain. Given these promising results, and the competitive nature of the pain field, BDSI has, as previously reported, elected to not disclose the active ingredient in BEMA(TM) LA at this time.

MORE ON THIS TOPIC